Bessemer Group
ARCT icon

Bessemer Group’s Arcturus Therapeutics ARCT Stock Holding History

Bessemer Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16
Closed – – 2478
2025
Q2 		$0 Hold
16
– – ﹤0.01% 2387
2025
Q1 		$0 Buy
+16
New +$254 ﹤0.01% 2430
2023
Q4 		– Sell
-300
Closed -$8K – 2136
2023
Q3 		$8K Buy
+300
New +$9.24K ﹤0.01% 1618

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Bessemer Group's ARCT Position: Q3 2025 in Review

Bessemer Group sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 16 shares.

Bessemer Group first reported a position in ARCT in Q3 2023 and held it in 3 quarters. The position peaked at $8K in Q3 2023. 137 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • Bessemer Group reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bessemer Group sold 16 Arcturus Therapeutics shares in Q3 2025.
  • Bessemer Group first reported a position in Arcturus Therapeutics in Q3 2023 and held it in 3 quarters.
  • Bessemer Group's Arcturus Therapeutics position peaked at $8K in Q3 2023.
  • 137 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.